<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162250</url>
  </required_header>
  <id_info>
    <org_study_id>GV39131</org_study_id>
    <secondary_id>2016-001880-35</secondary_id>
    <nct_id>NCT03162250</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics</brief_title>
  <official_title>A Phase IB, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib, randomized double-blind, placebo-controlled multiple-ascending dose study
      to investigate the safety, tolerability, and pharmacokinetics of multiple doses of DSTA4637S
      when given in addition to anti-staphylococcal SOC antibiotics to participants with
      methicillin-resistant staphylococcus aureus (MRSA) and methicillin-sensitive staphylococcus
      aureus (MSSA) bacteremia requiring at least 4 weeks of anti-staphylococcal SOC antibiotics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2017</start_date>
  <completion_date type="Actual">January 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Antibody-Conjugated 4-Dimethylamino Piperidino-Hydroxybenzoxazino Rifamycin (dmDNA31) measured by Plasma</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of DSTA4637S Total Antibody measured by Serum</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Unconjugated dmDNA31 measured by Plasma</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to DSTA4637S</measure>
    <time_frame>Baseline up to approximately 156 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>DSTA4637S low dose level + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSTA4637S intermediate dose level+ SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSTA4637S high dose level+ SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSTA4637S</intervention_name>
    <description>DSTA4637S will be administered as an IV infusion at 3 dose levels.</description>
    <arm_group_label>DSTA4637S high dose level+ SOC</arm_group_label>
    <arm_group_label>DSTA4637S intermediate dose level+ SOC</arm_group_label>
    <arm_group_label>DSTA4637S low dose level + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to DSTA4637S IV infusion will be administered as specified.</description>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.</description>
    <arm_group_label>DSTA4637S high dose level+ SOC</arm_group_label>
    <arm_group_label>DSTA4637S intermediate dose level+ SOC</arm_group_label>
    <arm_group_label>DSTA4637S low dose level + SOC</arm_group_label>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index greater than or equal (&gt;/=) 18 to less than or equal to (&lt;/=) 40
             kg/m^2

          -  At randomization, participants must have &gt;/=1 blood culture or molecular diagnostic
             that is positive for Staphylococcal aureus (S. aureus) collected in the previous 120
             hours

          -  In the investigator's judgment, an expected treatment duration for S. aureus
             intravenous infection with anti-staphylococcal SOC antibiotics &gt;/= 4 weeks

        Exclusion Criteria:

          -  The presence of an intravascular catheter that is not planned to be removed within 96
             hours of study randomization

          -  S. aureus bacteremia associated with an intracardiac device and/or intravascular
             prosthetic material (including hemodialysis access graft)

          -  In the investigator's judgement, S. aureus bacteremia involving infection of a
             prosthetic joint or vertebral hardware

          -  In participants with cirrhosis, a Child-Pugh Score of Class B or C

          -  Known rifampicin-resistant S. aureus

          -  Anticipated receipt of a rifamycin class (excluding rifaxamin) antibiotic from Day 1
             to study completion/discontinuation

          -  In the investigator's judgment, the need for emergent valve surgery at the time of
             randomization or a high likelihood of cardiac surgery within 3 days after
             randomization

          -  Polymicrobial bacteremia

          -  Participants with significant immune suppression

          -  Participants with evidence of liver disease

          -  History or presence of an abnormal electrocardiogram (ECG)

          -  Exposure to any biological therapy or investigational biological agent within 90 days
             prior to the screening evaluation or have received any other investigational treatment
             30 days prior to the screening evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Gyeongsangnam-do</city>
        <zip>52727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center - Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

